Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;27(20):2200350.
doi: 10.2807/1560-7917.ES.2022.27.20.2200350.

mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022

Marta Grgič Vitek  1 , Irena Klavs  1 , Veronika Učakar  1 , Marjana Vrh  1 , Maja Mrzel  1 , Mojca Serdt  1 , Mario Fafangel  1
Affiliations

mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022

Marta Grgič Vitek et al. Euro Surveill. 2022 May.

Abstract

For the period of predominance of SARS-CoV-2 Omicron variant in Slovenia, February to March 2022, we estimated mRNA vaccine effectiveness (VE) against severe acute respiratory infection (SARI) COVID-19 using surveillance data. In the most vulnerable age group comprising individuals aged 65 years and more, VE against SARI COVID-19 was 95% (95% CI: 95-96%) for those vaccinated with three doses, in comparison to 82% (95% CI: 79-84%) for those vaccinated with two doses. Such levels of protection were maintained for at least 6 months.

Keywords: COVID-19; Omicron variant; Slovenia; mRNA vaccines; severe acute respiratory infection (SARI); surveillance; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

References

    1. Grgič Vitek M, Klavs I, Učakar V, Serdt M, Mrzel M, Vrh M, et al. Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021. Euro Surveill. 2022;27(1):2101110. 10.2807/1560-7917.ES.2022.27.1.2101110 - DOI - PMC - PubMed
    1. National Laboratory of Health, Environment and Food (NLZOH). Sledenje različicam SARS CoV-2. [Surveillance of variants of SARS_CoV-2]. Available from: https://www.nlzoh.si/objave/sledenje-razlicicam-sars-cov-2-45/
    1. Klavs I, Serdt M, Učakar V, Grgič-Vitek M, Fafangel M, Mrzel M, et al. EPISARI Network. Members of the EPISARI Network . Enhanced national surveillance of severe acute respiratory infections (SARI) within COVID-19 surveillance, Slovenia, weeks 13 to 37 2021. Euro Surveill. 2021;26(42):2100937. 10.2807/1560-7917.ES.2021.26.42.2100937 - DOI - PMC - PubMed
    1. National institute of Public Health (NIJZ). Elektronski register cepljenih oseb in neželenih učinkov po cepljenju. [Electronic Registry of vaccinated individuals and adverse events following vaccinations]. Ljubljana: NIJZ. [Accessed: 2 Dec 2021]. Available from: https://www.nijz.si/sl/elektronski-register-cepljenih-oseb-in-nezelenih-...
    1. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. COVID-19 Genomics UK (COG-UK) consortium . Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303-12. 10.1016/S0140-6736(22)00462-7 - DOI - PMC - PubMed

Supplementary concepts